• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response letter regarding the letter to the editors by Brown et al.

作者信息

Taylor Sylvia, Ryser Martin, Mihalyi Attila, van Effelterre Thierry

机构信息

a GSK Vaccines , Wavre , Belgium.

出版信息

Hum Vaccin Immunother. 2016 Jul 2;12(7):1943-6. doi: 10.1080/21645515.2016.1151598. Epub 2016 May 10.

DOI:10.1080/21645515.2016.1151598
PMID:27163545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4964815/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6403/4964815/d464e8906df0/khvi-12-07-1151598-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6403/4964815/d464e8906df0/khvi-12-07-1151598-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6403/4964815/d464e8906df0/khvi-12-07-1151598-g001.jpg

相似文献

1
Response letter regarding the letter to the editors by Brown et al.关于布朗等人致编辑信的回复信
Hum Vaccin Immunother. 2016 Jul 2;12(7):1943-6. doi: 10.1080/21645515.2016.1151598. Epub 2016 May 10.
2
[Vaccination perspective against human papillomavirus and consequences for the screening of uterine cervical neoplasm].[人乳头瘤病毒疫苗接种前景及子宫颈肿瘤筛查的影响]
Bull Mem Acad R Med Belg. 2007;162(10-12):483-8; discussion 489-90.
3
Vaccination against human papillomavirus types 16 and 18: the impact on cervical cancer.针对16型和18型人乳头瘤病毒的疫苗接种：对宫颈癌的影响。
Future Oncol. 2010 Dec;6(12):1817-21. doi: 10.2217/fon.10.150.
4
Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.人乳头瘤病毒疫苗接种、细胞学检查与人乳头瘤病毒检测的整合
Cancer. 2007 Jun 25;111(3):145-53. doi: 10.1002/cncr.22751.
5
Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.智利女性人乳头瘤病毒疫苗的健康经济分析：基于马尔可夫模型的医疗保健支付方视角
BMC Public Health. 2014 Nov 26;14:1222. doi: 10.1186/1471-2458-14-1222.
6
A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.人乳头瘤病毒16/18 AS04佐剂宫颈癌疫苗对致癌性人乳头瘤病毒的交叉保护作用综述：病毒学和临床终点的重要性及其对宫颈癌预防大规模疫苗接种的影响
Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S18-25. doi: 10.1016/j.ygyno.2008.06.027. Epub 2008 Jul 23.
7
HPV vaccination: unanswered questions remain.人乳头瘤病毒疫苗接种：仍存在未解答的问题。
BJOG. 2015 Jan;122(1):118. doi: 10.1111/1471-0528.13069. Epub 2014 Sep 11.
8
HPV and cervical cancer: screening or vaccination?人乳头瘤病毒与宫颈癌：筛查还是接种疫苗？
Br J Cancer. 2008 Jan 15;98(1):15-21. doi: 10.1038/sj.bjc.6604146. Epub 2008 Jan 8.
9
[Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].[人乳头瘤病毒疫苗接种。宫颈癌防控中的实施与效果]
Bull Acad Natl Med. 2007 Dec;191(9):1805-16; discussion 1816-7.
10
Efficacy of vaccination against HPV infection to prevent cervical cancer in France.法国HPV感染疫苗预防宫颈癌的有效性。
Public Health. 2015 Jan;129(1):78-81. doi: 10.1016/j.puhe.2014.11.005. Epub 2014 Dec 24.

引用本文的文献

1
Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer.人乳头瘤病毒疫苗对癌症的有效性和效力
Vaccines (Basel). 2021 Nov 30;9(12):1413. doi: 10.3390/vaccines9121413.
2
Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea.与韩国单纯宫颈癌筛查相比，在宫颈癌筛查中增加两剂人乳头瘤病毒疫苗接种计划的成本效益分析
Asian Pac J Cancer Prev. 2019 Feb 26;20(2):425-435. doi: 10.31557/APJCP.2019.20.2.425.
3
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.

本文引用的文献

1
Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.人乳头瘤病毒（HPV）-16/18 AS04 佐剂疫苗用于预防宫颈癌和 HPV 相关疾病。
Expert Rev Vaccines. 2016;15(3):367-87. doi: 10.1586/14760584.2016.1124763.
2
Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.2009 - 2013年苏格兰引入疫苗接种计划后的人乳头瘤病毒流行率及群体免疫情况
Emerg Infect Dis. 2016 Jan;22(1):56-64. doi: 10.3201/eid2201.150736.
3
Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV.
接种人乳头瘤病毒预防性疫苗以预防宫颈癌及其癌前病变。
Cochrane Database Syst Rev. 2018 May 9;5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3.
4
Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.马来西亚两种不同两剂次人乳头瘤病毒疫苗的成本效益比较分析
Asian Pac J Cancer Prev. 2018 Apr 25;19(4):933-940. doi: 10.22034/APJCP.2018.19.4.933.
5
Letter-to-the-Editor in response to "Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001.".致编辑的信，回应《坦顿C等人。英国年轻女性中的人乳头瘤病毒（HPV）：基于人群的二价免疫计划有效性以及四价和九价疫苗类型负担的证据。乳头瘤病毒研究。2017年6月；3：36 - 41。doi：10.1016/j.pvr.2017.01.001》。
Papillomavirus Res. 2018 Jun;5:61-62. doi: 10.1016/j.pvr.2017.12.005. Epub 2017 Dec 20.
两种人乳头瘤病毒疫苗真的相似吗？现有证据的系统评价：两种疫苗对 HPV 的功效。
J Immunol Res. 2015;2015:435141. doi: 10.1155/2015/435141. Epub 2015 Aug 25.
4
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.少于三剂HPV-16/18 AS04佐剂疫苗的效力：哥斯达黎加疫苗试验和PATRICIA试验数据的联合分析
Lancet Oncol. 2015 Jul;16(7):775-86. doi: 10.1016/S1470-2045(15)00047-9. Epub 2015 Jun 9.
5
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.九价人乳头瘤病毒疫苗预防女性感染和上皮内瘤变。
N Engl J Med. 2015 Feb 19;372(8):711-23. doi: 10.1056/NEJMoa1405044.
6
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.人乳头瘤病毒（HPV）-16/18 AS04佐剂疫苗对年轻日本女性宫颈上皮内瘤变和宫颈感染的疗效。
Hum Vaccin Immunother. 2014;10(7):1781-94. doi: 10.4161/hv.28712.
7
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.12种高危型人乳头瘤病毒基因型与感染及宫颈疾病的关系
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1997-2008. doi: 10.1158/1055-9965.EPI-14-0410.
8
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.HPV 16/18 AS04 佐剂疫苗在 25 岁以上女性中的功效、安全性和免疫原性：3 期、双盲、随机对照 VIVIANE 研究的 4 年中期随访。
Lancet. 2014 Dec 20;384(9961):2213-27. doi: 10.1016/S0140-6736(14)60920-X. Epub 2014 Sep 1.
9
Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.不同人乳头瘤病毒血清学和 DNA 标准对疫苗效力估计的影响。
Am J Epidemiol. 2014 Sep 15;180(6):599-607. doi: 10.1093/aje/kwu168. Epub 2014 Aug 19.
10
Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule.两剂次或三剂次接种程序后接种 Cervarix 疫苗的受种者的抗体亲和力测定。
Vaccine. 2014 May 30;32(26):3232-6. doi: 10.1016/j.vaccine.2014.04.005. Epub 2014 Apr 13.